Robert Baltera Jr., Director at PALISADE BIO, INC. (PALI), bought 50,000 shares at $2.05 ($102K) on 2026-07-06, disclosed to the SEC on 2026-07-08.
Director Robert Baltera Jr. purchased 20,000 shares at $2.05, representing the largest insider purchase in the company's history. This bullish signal arrives as the stock has surged 19.6% over the past 30 days.
The stock is currently trading at $2.075, up 19.6% over the last 30 days, though it remains 27.19% below its 52-week high of $2.85.
FDA clearance for the Investigational New Drug application for PALI-2108 on 2026-06-29; Wolfe Research initiated coverage with an Outperform rating and $7 price target on 2026-04-17; and the company reported Q1 2026 earnings on 2026-05-18 with R&D expenses rising to $6.4M.
The stock faces elevated risk with short interest comprising 18.16% of the float.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.05 | 20,000 | $41K | 40.2% |
| 2 | $2.03 | 30,000 | $61K | 59.8% |
| Total | $2.04 avg | 50,000 | $102K | 100% |
| Filing → |
| IMGO | BUY | 2021-07-19 | $14K | — | Filing → |
| ONVO | SELL | 2015-09-23 | $24K | — | Filing → |